Published in Cardiovasc Res on February 12, 2007
PAI-1 in tissue fibrosis. J Cell Physiol (2012) 2.26
Possible mechanical roles of glycosaminoglycans in thoracic aortic dissection and associations with dysregulated transforming growth factor-β. J Vasc Res (2012) 2.16
Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood (2009) 1.59
Fibrogenesis of parenchymal organs. Proc Am Thorac Soc (2008) 1.53
Arterial stiffening with ageing is associated with transforming growth factor-β1-related changes in adventitial collagen: reversal by aerobic exercise. J Physiol (2010) 1.51
The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr (2012) 1.46
Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet (2010) 1.45
Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model. Europace (2012) 1.45
LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome. PLoS One (2007) 1.44
Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One (2012) 1.43
P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J (2008) 1.38
Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol (2011) 1.34
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost (2008) 1.30
Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol (2010) 1.25
Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am J Pathol (2009) 1.25
Estrogen receptor-beta prevents cardiac fibrosis. Mol Endocrinol (2010) 1.24
Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res (2010) 1.22
A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. PLoS One (2012) 1.20
Cerebral small vessel disease-related protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β signaling. Proc Natl Acad Sci U S A (2014) 1.19
Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail (2009) 1.17
Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis. Am J Physiol Heart Circ Physiol (2009) 1.17
Mechanism of dietary salt-mediated increase in intravascular production of TGF-beta1. Am J Physiol Renal Physiol (2008) 1.13
TGF-β and restenosis revisited: a Smad link. J Surg Res (2011) 1.10
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications. PLoS One (2009) 1.09
Ethanol (EtOH)-induced TGF-β1 and reactive oxygen species production are necessary for EtOH-induced alveolar macrophage dysfunction and induction of alternative activation. Alcohol Clin Exp Res (2012) 1.09
Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem (2010) 1.09
Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol (2007) 1.08
Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol (2008) 1.04
Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. Circ Res (2015) 1.04
Dietary salt intake, salt sensitivity, and cardiovascular health. Hypertension (2009) 1.03
Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One (2010) 1.01
Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. J Cell Mol Med (2008) 1.00
Consistent biomechanical phenotyping of common carotid arteries from seven genetic, pharmacological, and surgical mouse models. Ann Biomed Eng (2014) 0.99
Vascular wall extracellular matrix proteins and vascular diseases. Biochim Biophys Acta (2014) 0.99
A network study of chinese medicine xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway. Evid Based Complement Alternat Med (2013) 0.97
Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol (2008) 0.95
Possible mechanisms of kidney repair. Fibrogenesis Tissue Repair (2009) 0.95
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS One (2008) 0.95
Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med (2010) 0.94
An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis. Int J Exp Pathol (2008) 0.93
TSC-22 promotes transforming growth factor β-mediated cardiac myofibroblast differentiation by antagonizing Smad7 activity. Mol Cell Biol (2011) 0.92
Quantification of active and total transforming growth factor-β levels in serum and solid organ tissues by bioassay. BMC Res Notes (2012) 0.92
Poly(ADP-ribose) polymerase 1 is indispensable for transforming growth factor-β Induced Smad3 activation in vascular smooth muscle cell. PLoS One (2011) 0.92
Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein. Bioorg Med Chem Lett (2008) 0.92
Inorganic nitrite supplementation for healthy arterial aging. J Appl Physiol (1985) (2014) 0.91
LOXL4 is induced by transforming growth factor β1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. Mol Cell Biol (2013) 0.91
Cyclic GMP kinase and RhoA Ser188 phosphorylation integrate pro- and antifibrotic signals in blood vessels. Mol Cell Biol (2009) 0.91
Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex. J Cell Mol Med (2012) 0.90
Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res (2011) 0.89
Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling. Clin Sci (Lond) (2014) 0.87
Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiol Res Pract (2010) 0.86
Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice. Connect Tissue Res (2012) 0.85
Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats. PPAR Res (2012) 0.85
Angiotensin II contributes to renal fibrosis independently of Notch pathway activation. PLoS One (2012) 0.85
Vascular smooth muscle cell Smad4 gene is important for mouse vascular development. Arterioscler Thromb Vasc Biol (2012) 0.85
Sequestration of latent TGF-β binding protein 1 into CADASIL-related Notch3-ECD deposits. Acta Neuropathol Commun (2014) 0.85
Changes in Cx43 and NaV1.5 expression precede the occurrence of substantial fibrosis in calcineurin-induced murine cardiac hypertrophy. PLoS One (2014) 0.84
Preventive effect of halofuginone on concanavalin A-induced liver fibrosis. PLoS One (2013) 0.84
Prolonged fasting activates Nrf2 in post-weaned elephant seals. J Exp Biol (2013) 0.84
The periodontal pathogen Porphyromonas gingivalis changes the gene expression in vascular smooth muscle cells involving the TGFbeta/Notch signalling pathway and increased cell proliferation. BMC Genomics (2013) 0.84
Parathyroid hormone-related protein promotes epithelial-mesenchymal transition. J Am Soc Nephrol (2009) 0.84
Accelerated reendothelialization, increased neovascularization and erythrocyte extravasation after arterial injury in BAMBI-/- mice. PLoS One (2013) 0.83
Glucocorticoid modulates angiotensin II receptor expression patterns and protects the heart from ischemia and reperfusion injury. PLoS One (2014) 0.83
A role for soluble ST2 in vascular remodeling associated with obesity in rats. PLoS One (2013) 0.83
Transforming growth factor-beta signaling in hypertensive remodeling of porcine aorta. Am J Physiol Heart Circ Physiol (2009) 0.83
Role of TGF-β1/Smad3 signaling pathway in secretion of type I and III collagen by vascular smooth muscle cells of rats undergoing balloon injury. J Biomed Biotechnol (2012) 0.83
Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation (2011) 0.82
Update of genetic susceptibility in patients with Kawasaki disease. Korean J Pediatr (2015) 0.82
New Insights into Dialysis Vascular Access: Impact of Preexisting Arterial and Venous Pathology on AVF and AVG Outcomes. Clin J Am Soc Nephrol (2016) 0.82
MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circ Res (2014) 0.82
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol (2012) 0.82
Monogenic causes of stroke: now and the future. J Neurol (2015) 0.81
Transforming growth factor beta receptor II polymorphisms are associated with Kawasaki disease. Korean J Pediatr (2012) 0.81
Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. J Biol Chem (2012) 0.81
New molecular medicine-based scar management strategies. Burns (2014) 0.81
Molecular insights on the effect of TGF-β1/-β3 in human corneal fibroblasts. Exp Eye Res (2016) 0.81
Blockade of TGF-β by catheter-based local intravascular gene delivery does not alter the in-stent neointimal response, but enhances inflammation in pig coronary arteries. Int J Cardiol (2010) 0.80
TGF-beta inhibits IL-1beta-activated PAR-2 expression through multiple pathways in human primary synovial cells. J Biomed Sci (2009) 0.80
Reduced corporal fibrosis to protect erectile function by inhibiting the Rho-kinase/LIM-kinase/cofilin pathway in the aged transgenic rat harboring human tissue kallikrein 1. Asian J Androl (2016) 0.80
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease. Mol Med Ther (2012) 0.80
Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. Can J Cardiol (2016) 0.80
Orphan nuclear receptor small heterodimer partner inhibits angiotensin II- stimulated PAI-1 expression in vascular smooth muscle cells. Exp Mol Med (2010) 0.79
Inhibition of angiotensin II Gq signaling augments beta-adrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure. J Mol Cell Cardiol (2008) 0.79
Hemocoagulase atrox reduces vascular modeling in rabbit carotid artery adventitia. Int J Clin Exp Pathol (2013) 0.79
Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosis. Int J Mol Sci (2015) 0.78
Microvascular targets for anti-fibrotic therapeutics. Yale J Biol Med (2013) 0.78
Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway. Acta Pharmacol Sin (2012) 0.78
The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells. Antioxid Redox Signal (2015) 0.78
Mediators leading to fibrosis - how to measure and control them in tissue engineering. Oper Tech Orthop (2010) 0.78
Genetic polymorphism of SMAD5 is associated with Kawasaki disease. Pediatr Cardiol (2013) 0.78
Wnt16 attenuates TGFβ-induced chondrogenic transformation in vascular smooth muscle. Arterioscler Thromb Vasc Biol (2015) 0.78
Advances in biomimetic regeneration of elastic matrix structures. Drug Deliv Transl Res (2012) 0.78
TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2. Mediators Inflamm (2015) 0.78
Genetic analysis of the contribution of LTBP-3 to thoracic aneurysm in Marfan syndrome. Proc Natl Acad Sci U S A (2015) 0.77
Exosomes in carcinogenesis: molecular palkis carry signals for the regulation of cancer progression and metastasis. J Cell Commun Signal (2016) 0.77
The pathogenesis of aortopathy in Marfan syndrome and related diseases. Curr Cardiol Rep (2010) 0.77
Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study. Atherosclerosis (2015) 0.77
Freeze-dried allograft-mediated gene or protein delivery of growth and differentiation factor 5 reduces reconstructed murine flexor tendon adhesions. J Tissue Eng (2014) 0.77
Effect of high-fat diet upon inflammatory markers and aortic stiffening in mice. Biomed Res Int (2014) 0.77
Gremlin activates the Smad pathway linked to epithelial mesenchymal transdifferentiation in cultured tubular epithelial cells. Biomed Res Int (2014) 0.77
Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2007) 2.95
Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation (2005) 2.55
Biomarkers in cardiovascular medicine. Rev Esp Cardiol (2009) 2.34
Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res (2006) 1.81
NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant (2004) 1.78
Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int (2008) 1.77
Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant (2005) 1.76
Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol (2003) 1.67
The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis (2009) 1.59
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.55
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol (2009) 1.52
The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol (2008) 1.43
AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol (2011) 1.40
Anti-inflammatory and immunomodulatory effects of statins. Kidney Int (2003) 1.39
Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl (2003) 1.39
Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation (2004) 1.33
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis (2002) 1.31
Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens (2006) 1.26
Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.25
Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.22
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2009) 1.21
TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant (2009) 1.21
Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation (2003) 1.21
Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep (2003) 1.20
Biological significance of decreased HSP27 in human atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 1.16
Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res (2008) 1.15
Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res (2005) 1.15
Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension (2009) 1.14
Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res (2005) 1.14
Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.13
Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke (2006) 1.12
Olive oil and walnut breakfasts reduce the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy men. Atherosclerosis (2008) 1.11
Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol (2002) 1.09
Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc Diabetol (2013) 1.08
Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis (2005) 1.08
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol (2010) 1.07
TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One (2010) 1.07
Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med (2009) 1.07
3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes (2005) 1.07
Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol (2010) 1.05
HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension (2007) 1.03
Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One (2010) 1.01
Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res (2008) 1.01
Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl (2003) 1.01
3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int (2005) 1.01
Paracetamol-induced renal tubular injury: a role for ER stress. J Am Soc Nephrol (2004) 1.01
Butter and walnuts, but not olive oil, elicit postprandial activation of nuclear transcription factor kappaB in peripheral blood mononuclear cells from healthy men. Am J Clin Nutr (2004) 1.01
CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol (2009) 1.01
The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant (2010) 1.00
Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol (2003) 1.00
Glomerular haematuria, renal interstitial haemorrhage and acute kidney injury. Nephrol Dial Transplant (2010) 1.00
TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res (2010) 1.00
Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke (2003) 0.99
Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis (2011) 0.99
Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2006) 0.99
Expression of Smac/Diablo in tubular epithelial cells and during acute renal failure. Kidney Int Suppl (2003) 0.98
Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol (2004) 0.98
Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovasc Res (2009) 0.98
Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant (2008) 0.97
Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int Suppl (2003) 0.96
Pre-existing glomerular immune complexes induce polymorphonuclear cell recruitment through an Fc receptor-dependent respiratory burst: potential role in the perpetuation of immune nephritis. J Immunol (2003) 0.95
p-cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol Dial Transplant (2013) 0.95
NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke (2004) 0.95
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation (2003) 0.95
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke (2005) 0.95
Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev (2009) 0.95
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One (2013) 0.95
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS One (2008) 0.95
Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res (2005) 0.94
Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation. Atherosclerosis (2006) 0.94
HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. Lab Invest (2011) 0.94
Expression of gremlin, a bone morphogenetic protein antagonist, in glomerular crescents of pauci-immune glomerulonephritis. Nephrol Dial Transplant (2007) 0.94
Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol (2009) 0.93
Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. Kidney Int (2005) 0.93
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol (2006) 0.93
Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl (2003) 0.93
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens (2005) 0.93
Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol (2005) 0.93
Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant (2012) 0.92
Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res (2003) 0.92
Acute renal failure associated to paroxysmal nocturnal haemoglobinuria leads to intratubular haemosiderin accumulation and CD163 expression. Nephrol Dial Transplant (2011) 0.91
Haematuria: the forgotten CKD factor? Nephrol Dial Transplant (2012) 0.91
Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy. Nephron Clin Pract (2012) 0.91
The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Trends Cardiovasc Med (2007) 0.90
Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches. Curr Drug Targets Inflamm Allergy (2005) 0.90
A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS One (2009) 0.89
Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation. Arthritis Rheum (2008) 0.89